Phosphatidylinositol 4-kinase beta,Phosphatidylinositol 4-kinase beta
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain A； UniProt 317–428 Chain A； UniProt 532–798 | Not recorded | EMW (3~{S})-4-(6-azanyl-1-methyl-pyrazolo[3,4-d]pyrimidin-4-yl)-~{N}-(4-methoxy-2-methyl-phenyl)-3-methyl-piperazine-1-carboxamide × 1 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M sodium citrate, 22% (w/v) PEG3350, 10 mM Manganese(II)chloride | Resolution 2.77 Å R-free 0.333 |
| 2 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain B； UniProt 317–428 Chain B； UniProt 532–798 | Not recorded | No other associated polymer | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；293 K；0.2 M sodium citrate, 22% (w/v) PEG3350, 10 mM Manganese(II)chloride | Resolution 2.77 Å R-free 0.333 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 6GL3 | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 4D0L Phosphatidylinositol 4-kinase III beta-PIK93 in a complex with Rab11a- GTP gammaS Deposited 2014-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
121–407（287 aa）
Fragment：RESIDUES 121-407,508-784
Chain A
508–784（277 aa）
Fragment：RESIDUES 121-407,508-784
|
Mutation：YES Mutation：YES | 093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6；15% (W/V) PEG 4000, 0.1 M NA CITRATE PH 5.6, AND 0.2 M AMMONIUM ACETATE
|
Resolution 2.94 Å R-free 0.259 |
| 4D0L Phosphatidylinositol 4-kinase III beta-PIK93 in a complex with Rab11a- GTP gammaS Deposited 2014-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
121–407（287 aa）
Fragment：RESIDUES 121-407,508-784
Chain C
508–784（277 aa）
Fragment：RESIDUES 121-407,508-784
|
Mutation：YES Mutation：YES | 093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6；15% (W/V) PEG 4000, 0.1 M NA CITRATE PH 5.6, AND 0.2 M AMMONIUM ACETATE
|
Resolution 2.94 Å R-free 0.259 |
| 4D0L Phosphatidylinositol 4-kinase III beta-PIK93 in a complex with Rab11a- GTP gammaS Deposited 2014-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
121–407（287 aa）
Fragment：RESIDUES 121-407,508-784
Chain E
508–784（277 aa）
Fragment：RESIDUES 121-407,508-784
|
Mutation：YES Mutation：YES | 093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6；15% (W/V) PEG 4000, 0.1 M NA CITRATE PH 5.6, AND 0.2 M AMMONIUM ACETATE
|
Resolution 2.94 Å R-free 0.259 |
| 4D0M Phosphatidylinositol 4-kinase III beta in a complex with Rab11a-GTP- gamma-S and the Rab-binding domain of FIP3 Deposited 2014-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric |
Chain A
121–303（183 aa）
Chain A
319–421（103 aa）
Chain A
522–799（278 aa）
Chain C
121–303（183 aa）
Chain C
319–421（103 aa）
Chain C
522–799（278 aa）
Chain O
121–303（183 aa）
Chain O
319–421（103 aa）
Chain O
522–799（278 aa）
Chain S
121–303（183 aa）
Chain S
319–421（103 aa）
Chain S
522–799（278 aa）
|
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES | 093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 4 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 4 MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
16% PEG 6K, 0.01 M NA CITRATE
|
Resolution 6.00 Å R-free 0.359 |
| 4D0M Phosphatidylinositol 4-kinase III beta in a complex with Rab11a-GTP- gamma-S and the Rab-binding domain of FIP3 Deposited 2014-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric |
Chain G
121–303（183 aa）
Chain G
319–421（103 aa）
Chain G
522–799（278 aa）
Chain I
121–303（183 aa）
Chain I
319–421（103 aa）
Chain I
522–799（278 aa）
Chain M
121–303（183 aa）
Chain M
319–421（103 aa）
Chain M
522–799（278 aa）
Chain Q
121–303（183 aa）
Chain Q
319–421（103 aa）
Chain Q
522–799（278 aa）
|
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES | 093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 4 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 4 MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
16% PEG 6K, 0.01 M NA CITRATE
|
Resolution 6.00 Å R-free 0.359 |
| 4D0M Phosphatidylinositol 4-kinase III beta in a complex with Rab11a-GTP- gamma-S and the Rab-binding domain of FIP3 Deposited 2014-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric |
Chain W
121–303（183 aa）
Chain W
319–421（103 aa）
Chain W
522–799（278 aa）
Chain Y
121–303（183 aa）
Chain Y
319–421（103 aa）
Chain Y
522–799（278 aa）
Chain c
121–303（183 aa）
Chain c
319–421（103 aa）
Chain c
522–799（278 aa）
Chain g
121–303（183 aa）
Chain g
319–421（103 aa）
Chain g
522–799（278 aa）
|
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES | 093 N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE × 4 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 4 MG MAGNESIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
16% PEG 6K, 0.01 M NA CITRATE
|
Resolution 6.00 Å R-free 0.359 |
| 4WAE Phosphatidylinositol 4-kinase III beta crystallized with ATP Deposited 2014-08-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
128–422（295 aa）
Fragment：UNP residues 130-422, UNP residues 523-799
Chain A
523–799（277 aa）
Fragment：UNP residues 130-422, UNP residues 523-799
|
Not recorded | ATP ADENOSINE-5'-TRIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；10% w/v PEG 4000, 20% v/v glycerol
0.1 M MOPS/HEPES-Na pH 7.5
|
Resolution 3.32 Å R-free 0.244 |
| 4WAG Phosphatidylinositol 4-kinase III beta crystallized with MI103 inhibitor Deposited 2014-08-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
128–422（295 aa）
Fragment：UNP residues 128-422, UNP residues 523-799
Chain A
523–799（277 aa）
Fragment：UNP residues 128-422, UNP residues 523-799
|
Not recorded | 3K7 6-chloro-3-(3,4-dimethoxyphenyl)-2-methylimidazo[1,2-b]pyridazin-8-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；10% w/v PEG 4000, 20% v/v glycerol
0.1 M MOPS/HEPES-Na pH 7.5
|
Resolution 3.41 Å R-free 0.251 |
| 5C46 Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta in complex with GTP gamma S loaded Rab11 Deposited 2015-06-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
121–248（128 aa）
Chain E
288–407（120 aa）
Chain E
508–784（277 aa）
|
Mutation：S294A Mutation：S294A Mutation：S294A | SO4 SULFATE ION × 2 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 MG MAGNESIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；290 K；PEG-4000, sodium citrate, ammonium sulfate, glycerol
|
Resolution 2.65 Å R-free 0.246 |
| 5C4G Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta with the inhibitor BQR695 in complex with GDP loaded Rab11 Deposited 2015-06-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
121–248（128 aa）
Chain E
288–407（120 aa）
Chain E
508–784（277 aa）
|
Mutation：S294A Mutation：S294A Mutation：S294A | MG MAGNESIUM ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 SO4 SULFATE ION × 2 BQR N~2~-[7-(3,4-dimethoxyphenyl)quinoxalin-2-yl]-N-methylglycinamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.6；290 K；PEG-4000, sodium citrate, ammonium sulfate, glycerol
|
Resolution 3.20 Å R-free 0.287 |
| 5EUQ Crystal structure of an engineered construct of phosphatidylinositol 4 kinase III beta with a potent and selective inhibitor in complex with GDP loaded Rab11 Deposited 2015-11-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
121–248（128 aa）
Chain E
523–799（277 aa）
|
Mutation：S294A Mutation：S294A | GDP GUANOSINE-5'-DIPHOSPHATE × 1 SO4 SULFATE ION × 2 5S8 ~{N}-[5-[3-[[(4-hydroxyphenyl)amino]-bis(oxidanyl)-$l^{4}-sulfanyl]-4-methoxy-phenyl]-4-methyl-1,3-thiazol-2-yl]cyclopentanecarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.6；290 K；PEG-4000, sodium citrate, ammonium sulfate, glycerol
|
Resolution 3.20 Å R-free 0.266 |
| 5FBL PI4KB in complex with Rab11 and the MI356 Inhibitor Deposited 2015-12-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
128–422（295 aa）
Fragment：UNP Residues 128-422, 523-799
Chain A
523–799（277 aa）
Fragment：UNP Residues 128-422, 523-799
|
Not recorded | 5W9 ~{N}-[2-[[6-chloranyl-3-(4-methoxy-3-morpholin-4-ylsulfonyl-phenyl)-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethyl]ethanamide × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；1M Lithium chloride, 0.1M Citric acid pH=5, 10% (w/v) PEG 6000
|
Resolution 3.37 Å R-free 0.269 |
| 5FBQ PI4KB in complex with Rab11 and the MI358 Inhibitor Deposited 2015-12-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
128–422（295 aa）
Fragment：UNP Residues 128-422, 523-799
Chain A
523–799（277 aa）
Fragment：UNP Residues 128-422, 523-799
|
Not recorded | 5W6 ~{N}-[2-[[6-chloranyl-3-[3-[4-(hydroxymethyl)piperidin-1-yl]sulfonyl-4-methoxy-phenyl]-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethyl]ethanamide × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M magnesium chloride, 0.1M Tris PH=7, 10% (w/v) PEG 8000
|
Resolution 3.79 Å R-free 0.302 |
| 5FBR PI4KB in complex with Rab11 and the MI359 Inhibitor Deposited 2015-12-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
128–422（295 aa）
Fragment：UNP Residues 128-422, 523-799
Chain A
523–799（277 aa）
Fragment：UNP Residues 128-422, 523-799
|
Not recorded | 5W7 ~{N}-[2-[[3-[3-[(4-azanylcyclohexyl)sulfamoyl]-4-methoxy-phenyl]-6-chloranyl-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethyl]ethanamide × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.15M amonium sulfate, 0.1M MES pH=6, 15% PEG 4000
|
Resolution 3.28 Å R-free 0.264 |
| 5FBV PI4KB in complex with Rab11 and the MI364 Inhibitor Deposited 2015-12-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
128–422（295 aa）
Fragment：UNP Residues 128-422, 523-799
Chain A
523–799（277 aa）
Fragment：UNP Residues 128-422, 523-799
|
Not recorded | 5W3 ~{N}-[2-[[6-chloranyl-3-[3-(2-hydroxyethylsulfamoyl)-4-methoxy-phenyl]-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethy l]ethanamide × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.15M amonium sulfate, 0.1M MEW pH=6, 15% PEG 4000
|
Resolution 3.29 Å R-free 0.281 |
| 5FBW PI4KB in complex with Rab11 and the MI369 Inhibitor Deposited 2015-12-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
128–422（295 aa）
Fragment：UNP Residues 128-422, 523-729,UNP Residues 128-422, 523-729
Chain A
191–467（277 aa）
Fragment：UNP Residues 128-422, 523-729,UNP Residues 128-422, 523-729
|
Not recorded | 5W8 ~{N}-[2-[[6-chloranyl-3-[4-methoxy-3-[[(2~{R})-1-oxidanylbutan-2-yl]sulfamoyl]phenyl]-2-methyl-imidazo[1,2-b]pyridazin-8-yl]amino]ethyl]ethanamide × 1 GSP 5'-GUANOSINE-DIPHOSPHATE-MONOTHIOPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.2M ammonium sulfate, 0.1M MES pH=6.5, 20% (w/v) PEG 8000
|
Resolution 3.49 Å R-free 0.283 |
| 5NAS Crystal structure of human 14-3-3 zeta in complex with PI4KIIIB peptide Deposited 2017-02-28 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
289–297（9 aa）
Fragment：UNP residues 289-297
Chain D
289–297（9 aa）
Fragment：UNP residues 289-297
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；MES, PEG, ethylene glycol
|
Resolution 2.08 Å R-free 0.231 |
| 8Q6F HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 4) Deposited 2023-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
291–415（125 aa）
|
Mutation：R409Q,R412Q | KHR 3-(3-fluorosulfonyloxy-4-methoxy-phenyl)-2,5-dimethyl-7-(pyridin-4-ylmethylamino)pyrazolo[1,5-a]pyrimidine × 1 MG MAGNESIUM ION × 1 EDO 1,2-ETHANEDIOL × 7 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Sodium Formate
|
Resolution 1.51 Å R-free 0.224 |
| 8Q6G HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 8) Deposited 2023-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
291–415（125 aa）
|
Mutation：R409Q,R412Q | KIH 3-(3,4-dimethoxyphenyl)-7-[(4-fluorosulfonyloxyphenyl)methylamino]-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine × 1 MG MAGNESIUM ION × 1 EDO 1,2-ETHANEDIOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Sodium Formate
|
Resolution 1.54 Å R-free 0.221 |
| 8Q6H HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 11) Deposited 2023-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
291–415（125 aa）
|
Mutation：R409Q,R412Q | MG MAGNESIUM ION × 1 KI7 3-(3-fluorosulfonyloxy-4-methoxy-phenyl)-7-[(4-fluorosulfonyloxyphenyl)methylamino]-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Sodium Formate
|
Resolution 1.94 Å R-free 0.237 |
| 8VOF GI targeted CpPI4K inhibitor Deposited 2024-01-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
121–407（287 aa）
|
Mutation：L294A,L374Y,P597Y | A1ADE methyl 2-chloro-5-(methyl{(8R)-3-[4-(methylcarbamoyl)phenyl]pyrazolo[1,5-a]pyridine-5-carbonyl}amino)benzoate × 1 SO4 SULFATE ION × 1 GDP GUANOSINE-5'-DIPHOSPHATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；294 K；0.5M ammonium sulfate, 0.088M sodium citrate, 0.875M lithium sulfate, 2.4% glycerol, 2.5% ethylene glycol, 50mM HEPES pH 6.8
|
Resolution 3.00 Å R-free 0.270 |
17 other PDB entries and 21 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | PI4KB_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 2–113； UniProt 317–428 Author chain A； PDBConstruct 120–386； UniProt 532–798 Author chain B； PDBConstruct 2–113； UniProt 317–428 Author chain B； PDBConstruct 120–386； UniProt 532–798 |
